Branded Legacy Subsidiary Files Provisional Patent for Innovative Intranasal Drug Delivery Platform

Branded Legacy, Inc. (OTC: BLEG) announced that its subsidiary BioLegacy Evaluative Group Inc. has filed a provisional patent application with the U.S. Patent and Trademark Office for a novel intranasal drug delivery platform. The technology, named "Air-Driven Unitary Intranasal Drug Delivery Device for Stable and Reconstitutable Medicaments," represents a significant advancement in drug administration methods, particularly for emergency and precision medicine applications.

The compact, air-powered platform is engineered to provide precise, reliable, and cost-effective intranasal dosing. This innovation addresses critical challenges in drug delivery, especially for medications that require accurate dosing in emergency situations. The device is designed to work with both stable formulations, such as naloxone used for opioid overdose reversal, and unstable drugs that require on-demand reconstitution before administration.

This development comes at a crucial time when the opioid crisis continues to claim lives across the United States, making reliable and accessible overdose reversal tools increasingly important. The intranasal delivery method offers several advantages over traditional injection methods, including easier administration by non-medical personnel, reduced risk of needle-stick injuries, and potentially faster absorption in emergency situations.

The provisional patent filing through the U.S. Patent and Trademark Office establishes Branded Legacy's position in the competitive drug delivery technology space. The company's strategic collaborations with leading research institutions, including McMaster University and Stanford University, provide strong scientific backing for this innovation. These partnerships enhance the credibility and potential effectiveness of the developed technology.

Branded Legacy's state-of-the-art GMP manufacturing facility in Vancouver positions the company to potentially scale production if the technology receives full patent approval and regulatory clearance. The facility's advanced production capabilities could enable efficient manufacturing of the delivery devices once they move from development to commercialization phases.

The intranasal drug delivery market represents a growing segment within the pharmaceutical industry, driven by increasing preference for non-invasive administration methods and the need for rapid-acting medications. Branded Legacy's focus on both stable and reconstitutable medicaments broadens the potential applications of their technology beyond emergency use to include various therapeutic areas requiring precise nasal delivery.

This patent filing underscores Branded Legacy's commitment to addressing public health challenges through innovative solutions. The company's dedication to pioneering solutions in addiction treatment and harm reduction aligns with growing global efforts to combat substance use disorders and improve emergency medical response capabilities. For additional details about this development, visit https://ibn.fm/4ACgT.